Skip to content

Fatty liver present in 40% of HIV/HCV coinfected patients: drug choice and weight may contribute

Fibrosis progression may be faster than expected in HCV/HIV-coinfected patients

ICAAC: HIV / HCV coinfected patients with fibrosis get little benefit and a lot of side-effects from interferon / ribavirin

Progression of liver fibrosis may be speeded by nevirapine

HAART does not protect HIV/HCV patients from fibrosis, but nor does it worsen it

No difference in post-liver transplant survival between HAART-treated HIV-positive and HIV-negative

Few HIV-positive Italians candidates for liver transplant if strict criteria used

HAART does not prevent quicker rate of fibrosis in HIV/HCV coinfected patients, says study

Liver transplant after nevirapine reaction